---

1 Sep 2008 : Column 1662W—continued

temsirolimus for mantle cell lymphoma relapsed and/or refractory;

bevacizumab for breast cancer;

erlotinib in combination with bevacizumab for advanced or metastatic non-small cell lung cancer;

rituximab for follicular non-Hodgkin’s lymphoma;

vandetanib for thyroid cancer;

vandetanib for non small cell lung cancer;

trastuzumab for gastric cancer; and

trabectedin for relapsed ovarian cancer.

NICE commences work on technology appraisals once a final referral has been made by the Department.

Mr. Lansley: To ask the Secretary of State for Health (1) when chemotherapy providers will begin returning an agreed dataset on all patients receiving chemotherapy, as referred to in paragraph 4.52 of his Department’s Cancer Reform Strategy; what information is captured by the dataset; and if he will make a statement; [220959]

(2) when he expects the National Chemotherapy Advisory Group to have defined the information on chemotherapy to be submitted by NHS trusts to cancer registries. [220976]

Ann Keen: A small working group is currently scoping the requirements for chemotherapy data alongside a comparison of data items for chemotherapy that are already included within the National Cancer Dataset. Any dataset agreed will also include the requirements of the cancer registration dataset.

It is anticipated, subject to testing and approval by the NHS Information Standards Board, that implementation could begin by the end of 2009.

Mr. Lansley: To ask the Secretary of State for Health what assessment he has made of the robustness of chemotherapy cost data submitted as part of the 2007-08 NHS reference cost collection. [220960]

Ann Keen: No assessment has been made. 2007-08 NHS reference cost data has not yet been collected.

1 Sep 2008 : Column 1663W

Mr. Lansley: To ask the Secretary of State for Health how many patients in each (a) cancer network and (b) strategic health authority area received (i) chemotherapy for small cell lung cancer and (ii) chemotherapy for non-small cell lung cancer in each year since 1997-98. [220989]

Mr. Watson: I have been asked to reply.

The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.

Letter from Karen Dunnell, dated 1 September 2008:

1 Sep 2008 : Column 1664W

As National Statistician, I have been asked to reply to your recent parliamentary question asking how many patients in each (a) cancer network and (b) strategic health authority area received (i) chemotherapy for small cell lung cancer and (ii) chemotherapy for non-small cell lung cancer in each year since 1997-98. [220989]

The latest year for which data are available on the national cancer registry database, which ONS operates on behalf of the Department of Health, is 2005. Tables 1 and 2 show the number of cases of small and non-small cell lung cancer, newly diagnosed in each of the years 1997-2005 in the specified geographical areas, initially receiving chemotherapy. In 55 per cent. of lung cancer cases in the database, either no treatment information was recorded or patients were recorded as having had no treatment. 10 per cent. of cases was recorded as receiving more than one treatment.

1 Sep 2008 : Column 1665W

1 Sep 2008 : Column 1666W

Table: 1 Registrations of newly diagnosed cases of small cell lung cancer( 1) receiving chemotherapy treatment( 2) , by strategic health authority and Cancer Network( 3) , England, 1997-2005
	1997	1998	1999	2000	2001	2002	2003	2004	2005
England	1,614	1,785	1,896	2,035	1,836	1,647	1,634	1,750	1,727
Strategic Health Authority
North East	131	248	259	255	201	210	218	223	227
North West	257	219	282	296	248	148	239	264	248
Yorkshire and the Humber	275	304	272	315	273	298	272	271	253
East Midlands	92	99	116	129	101	97	94	91	85
West Midlands	145	162	180	192	180	159	141	167	156
East of England	172	200	188	193	213	170	159	203	173
London	228	235	231	291	250	220	228	200	230
South East Coast	118	142	132	137	123	136	116	130	131
South Central	66	67	77	112	96	75	68	56	77
South West	130	109	159	115	151	134	99	145	147
Cancer network
3 Counties	23	19	17	27	26	24	20	32	26
Anglia	83	94	85	98	103	90	83	110	96
Arden	28	34	38	39	32	24	43	43	25
Avon, Somerset and Wiltshire	38	29	51	29	36	29	24	60	50
Central South Coast	6	12	29	34	34	23	12	22	22
Derby/Burton	13	9	12	12	14	13	13	11	9
Dorset	11	8	12	17	31	23	12	26	27
Essex	49	62	59	56	64	55	47	59	48
Greater Manchester and Cheshire	194	140	140	156	141	67	138	161	141
Greater Midlands	42	56	71	78	71	75	47	59	81
Humber and Yorkshire Coast	59	60	68	63	51	58	64	70	65
Kent and Medway	63	55	65	58	52	57	47	49	62
Lancashire and South Cumbria	48	63	58	67	65	64	81	88	81
Leicestershire Northants and Rutland	37	45	51	39	42	33	29	38	34
Merseyside and Cheshire	3	2	65	53	26	11	5	6	14
Mid Trent	41	39	41	54	33	40	44	37	26
Mount Vernon	33	31	34	31	33	17	21	25	17
North East London	50	58	54	62	52	48	62	45	40
North London	36	59	53	50	46	46	39	37	44
North of England	154	273	286	284	220	227	248	234	247
North Trent	40	40	36	51	41	50	35	34	35
Pan Birmingham	65	59	61	62	62	45	38	40	36
Peninsula	62	58	78	46	62	65	45	35	50
South East London	64	60	52	79	59	50	50	44	74
South West London	51	49	58	72	55	46	47	55	48
Surrey, West Sussex and Hampshire	24	30	32	35	35	29	25	34	30
Sussex	27	47	27	37	31	38	37	34	29
Thames Valley	59	65	57	85	68	57	66	50	62
West London	41	28	30	42	55	48	41	36	44
Yorkshire	170	201	176	219	196	195	171	176	164
(1) Lung cancer is coded to C34 in the International Classification of Diseases Tenth Revision (ICD-10) (2) More than one type of treatment was recorded for some cases. (3) Cancer Network boundaries as at January 2008. Source: Office for National Statistics

---